UCSF

Tagged: TRANSPERS

Research outlines challenges for adoption of new genetic tests

Every day, on average, ten new genetic tests become commercially available to help doctors and patients make more informed decisions about health care.

Phillips discusses insurance coverage for genomic testing

Kathryn Phillips, PhD, discusses insurance coverage for genomic testing in her recent articles published in JAMA and Science.

In a JAMA Viewpoint, April 16, Phillips examines the new CMS coverage policy for genomic tests in cancer patients: “Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?

Study Identifies Lack of Information about HER2 Testing Practices

Breast cancer patients might not be getting full advantage from a genetic screening test for the protein known as HER2 to help determine if the use of trastuzumab (marketed as Herceptin) is the best course of treatment for them. For patients whose breast cancer cells produce excessive amounts of HER2, trastuzumab can be highly effective.